Testing a blood DNA marker to help diagnose ovarian cancer
Studies circulating tumor DNA in blood to tell benign from malignant ovarian masses.
Plain-language title generated from the registry record
Registry title: Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker
Key facts
- Where
- Aarhus, DenmarkSee the site
Where in Denmark
- Department of Gynaecology and Obstetrics, Aarhus University HospitalAarhus, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT05763511
- Record updated
- 9 May 2024
- Original description
This project investigates circulating tumor DNA (ctDNA) in patients with suspected ovarian malignancy.Read full original descriptionShow less
Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker
This project investigates circulating tumor DNA (ctDNA) in patients with suspected ovarian malignancy.
We hypothesize that measurement of ctDNA in women with suspected ovarian cancer can improve the diagnostic efficiency for preoperative differentiation between benign and malignant masses.
Specifically, we hope to determine the diagnostic efficiency of ctDNA alone and ctDNA in combination with imaging modalities (ultrasonography, MRI, PET-CT) and CA 125 for preoperative differentiation between benign and malignant adnexal masses. Based on this, we hope to develop an improved diagnostic algorithm.
The mutational profile and relation to tumour type, stage, treatment response and prognosis will be explored.
Analyses of blood and tissue samples will be used to examine the disease development and biology.
Blood samples, tumour tissue and data on imaging modalities as well as CA 125 will be collected prospectively in consecutive women referred to Aarhus University Hospital.
Inclusion: Suspected ovarian neoplasm; Informed consent.
Exclusion: Previous ovarian cancer diagnosis; Inability to give informed consent.